{"name":"Alcon Research","slug":"alcon-research","ticker":"","exchange":"","domain":"alconresearch.com","description":"Alcon Research is a leading eye care company dedicated to developing innovative solutions for vision care. With a robust pipeline of over 269 drugs in various stages of development, the company focuses on advancing treatments for a wide range of ocular conditions.","hq":"","founded":0,"employees":"~15,000","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"oncology","drugs":[{"name":"Fluticasone Propionate Nasal Spray, 50 mcg","genericName":"Fluticasone Propionate Nasal Spray, 50 mcg","slug":"fluticasone-propionate-nasal-spray-50-mcg","indication":"Other","status":"marketed"},{"name":"Maxidex","genericName":"Maxidex","slug":"maxidex","indication":"Other","status":"marketed"},{"name":"Timolol gel forming solution, 0.5%","genericName":"Timolol gel forming solution, 0.5%","slug":"timolol-gel-forming-solution-0-5","indication":"Other","status":"marketed"},{"name":"Triamcinolone Acetonide Injectable Suspension","genericName":"Triamcinolone Acetonide Injectable Suspension","slug":"triamcinolone-acetonide-injectable-suspension","indication":"Other","status":"marketed"},{"name":"Apraclonidine Hydrochloride Ophthalmic Solution","genericName":"Apraclonidine Hydrochloride Ophthalmic Solution","slug":"apraclonidine-hydrochloride-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Brinzolamide 1% added to Travoprost 0.004%","genericName":"Brinzolamide 1% added to Travoprost 0.004%","slug":"brinzolamide-1-added-to-travoprost-0-004","indication":"Other","status":"marketed"},{"name":"Brinzolamide 1% ophthalmic suspension AZOPT®","genericName":"Brinzolamide 1% ophthalmic suspension AZOPT®","slug":"brinzolamide-1-ophthalmic-suspension-azopt","indication":"Other","status":"marketed"},{"name":"Habitual prostaglandin monotherapy","genericName":"Habitual prostaglandin monotherapy","slug":"habitual-prostaglandin-monotherapy","indication":"Other","status":"marketed"},{"name":"Healon","genericName":"Healon","slug":"healon","indication":"Other","status":"marketed"},{"name":"Nepafenac 0.1%","genericName":"Nepafenac 0.1%","slug":"nepafenac-0-1","indication":"Other","status":"marketed"},{"name":"Travacom","genericName":"Travacom","slug":"travacom","indication":"Other","status":"marketed"},{"name":"Travoprost 0.004% BAK-free","genericName":"Travoprost 0.004% BAK-free","slug":"travoprost-0-004-bak-free","indication":"Other","status":"marketed"},{"name":"brinzolamide 1.0%","genericName":"brinzolamide 1.0%","slug":"brinzolamide-1-0","indication":"Other","status":"marketed"},{"name":"quinolone","genericName":"quinolone","slug":"quinolone","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Azopt","genericName":"Azopt","slug":"azopt","indication":"Ocular hypertension","status":"marketed"},{"name":"Travatan","genericName":"Travatan","slug":"travatan","indication":"Ocular hypertension","status":"marketed"}]}],"pipeline":[{"name":"Fluticasone Propionate Nasal Spray, 50 mcg","genericName":"Fluticasone Propionate Nasal Spray, 50 mcg","slug":"fluticasone-propionate-nasal-spray-50-mcg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Maxidex","genericName":"Maxidex","slug":"maxidex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Timolol gel forming solution, 0.5%","genericName":"Timolol gel forming solution, 0.5%","slug":"timolol-gel-forming-solution-0-5","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Triamcinolone Acetonide Injectable Suspension","genericName":"Triamcinolone Acetonide Injectable Suspension","slug":"triamcinolone-acetonide-injectable-suspension","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apraclonidine Hydrochloride Ophthalmic Solution","genericName":"Apraclonidine Hydrochloride Ophthalmic Solution","slug":"apraclonidine-hydrochloride-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azopt","genericName":"Azopt","slug":"azopt","phase":"marketed","mechanism":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Brinzolamide 1% added to Travoprost 0.004%","genericName":"Brinzolamide 1% added to Travoprost 0.004%","slug":"brinzolamide-1-added-to-travoprost-0-004","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brinzolamide 1% ophthalmic suspension AZOPT®","genericName":"Brinzolamide 1% ophthalmic suspension AZOPT®","slug":"brinzolamide-1-ophthalmic-suspension-azopt","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Habitual prostaglandin monotherapy","genericName":"Habitual prostaglandin monotherapy","slug":"habitual-prostaglandin-monotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Healon","genericName":"Healon","slug":"healon","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nepafenac 0.1%","genericName":"Nepafenac 0.1%","slug":"nepafenac-0-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Travacom","genericName":"Travacom","slug":"travacom","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Travatan","genericName":"Travatan","slug":"travatan","phase":"marketed","mechanism":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Travoprost 0.004% BAK-free","genericName":"Travoprost 0.004% BAK-free","slug":"travoprost-0-004-bak-free","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"brinzolamide 1.0%","genericName":"brinzolamide 1.0%","slug":"brinzolamide-1-0","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"quinolone","genericName":"quinolone","slug":"quinolone","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNRWd3eEVmSVNCRUJYeHFJeXVoZ2t3Zm13cm1kRTFYempqcllfR2syYWlWdUJEbVdxeVdnTGx2aVVyNk9FSDUzckRjLVRpRE5wM0kzcjNQOGRzMUtkUHNCVnVoRTVFVzZSa3pIcUlGMUNHRlhDbHFWaXFBdWVXVEMwYnp4ekRMenhqR1ZXWWF5TkdFOVZVYzVPX3dHdldrbjg2VW4w?oc=5","date":"2026-04-01","type":"pipeline","source":"Tracxn","summary":"List of 19 Acquisitions by Alcon (Apr 2026) - Tracxn","headline":"List of 19 Acquisitions by Alcon (Apr 2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVk0yWDVYWjhXdUNzMG8yMGFYeUpEeDNjSEVvTUhyWHkzVTN6cE9TQnpoZlh4NUE0TVBUQXlQMHBPUzl4SmhtM2hvUWZLbHVuZzUwTmQ5eDZYWERWUEM1STVsS3k5TzA2VktQampHRXBnY2F4Q2NJendGVGVpX1RKSFFMNy0tTmRXdVFLcUg1ZWllajkxeHhPSWRqcFRudzA3QWloX0JReGpDTmZ5Rm5tUnBEQzB1Y3hPUkFZS0VHZWxKZm9PZGVkazdrd2lteHY4dWRlaWMyVXUtNGQ4eExDUEFn?oc=5","date":"2026-02-24","type":"earnings","source":"Reuters","summary":"Eye-care group Alcon expects product launches to drive 2026 sales, profitability - Reuters","headline":"Eye-care group Alcon expects product launches to drive 2026 sales, profitability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPU3NhdkxuY3VJVkRhNWtCVTlmR2pOZFFqMHRSQ0MwWHh6V25aNGxTb3Z6ZlZrU1gxcnJsdV9TRUxhcEdFaDRjaU1rMHBoX3BDRGk4ajZWalhZTEU5SjBuWThhR1ZqWlVEWm9Lam4weVo5d2NHcnFTb0N1MkFqbUNHN2htTENld00ycDRsVDJQTlVocFdaTFZQQXU3NHJkaUZ2azVPLWRneUFWbnVNTkVRcjJmaTFsdVRrUkRZTmZaSll5VHlNaURLTnBUblRKX091NmRnd2Fadl9VeElhODNlOW9rd2pNMG5BOGNnV2E4aGZZNjJTaEVhTDVB0gH_AUFVX3lxTE9pRXNoYzU2M3RtMG14TlZEQWtvVWtDbHNiNGlnSVdkMVFwRnZnb2hJUjdSemFobVJCMzJwbENlS2ZGV0dBQVdZV1NwUl9hWmlfTkRDYUtXU3dLRmN2TzZCUU5wNlVtSUlQSy1UTWUtVDQ0emNtd1k4MlpoWnJmb3ZhT2pUOGpmeU9aOGVtYjR3S3ZvcVlnb3pPWGNvUWpQb1VELUYzU3pWZllEN2thSklMNG5DVHdfT2RpRk5vM3d3UV9YWExzR3EzM0ZOeEVWaFplenBvczV0bENMWlRzNkl2UUR6cXBkQXJSZE1hdnVuaXZ2WmxBWjA1bkJsZ1ItRQ?oc=5","date":"2026-01-19","type":"pipeline","source":"Medical Dialogues","summary":"Alcon India Gets Rs 25 Cr Tax Relief as ITAT Bengaluru Quashes Advertising, Marketing and Promotion... - Medical Dialogues","headline":"Alcon India Gets Rs 25 Cr Tax Relief as ITAT Bengaluru Quashes Advertising, Marketing and Promotion...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOajhyRF9hNEF5UGhXN3RSLXpQZDlqM1JySXA5cV8zNmpUclA2UTRTTTlVYWdhWG5aX2RCM25qLUU4SFliYVctNmVrTWJqRGZpWmtSRzR0Ukp2UTBncS1XeWhHRm03amota3lUOUJfQTNocXhLUml1VjNHZ1FzME11NExHWDZWLVpPV2c1eWxfY2NrMHd3UVE?oc=5","date":"2025-10-01","type":"regulatory","source":"Fort Worth Inc.","summary":"Fort Worth City Council Approves $6M Incentives for Potential $186M Alcon Expansion - Fort Worth Inc.","headline":"Fort Worth City Council Approves $6M Incentives for Potential $186M Alcon Expansion","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQRjc2bk84c1l0MnFsQUdtSlRPVGZXVG55V21sQVBwN2ZnU3BKVDNTdjZIY0JFV0Q3OEFVUEx5S1diQ3BhRUh2SjNNaHNQdEhac1BWbnE3N1Q4bGVDSldmN3V6TDlnRHBqeTRrcDhndWJDTlZNMU5ZWjM4YjJYbUVtR1FjNVNYYTg1VDVVeDlpdmJLa215aXpXdGF1YWJ1SkxmUTNpXzNDZFBnS2JxdGtv?oc=5","date":"2025-09-25","type":"pipeline","source":"Fort Worth Report","summary":"Alcon’s potential manufacturing moves have Fort Worth eyeing tax breaks - Fort Worth Report","headline":"Alcon’s potential manufacturing moves have Fort Worth eyeing tax breaks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxONXNUdERNUjB1Tk9iTUlmUXhubDFMdzliZjNXVHgzSGJtUjdZUmVPcGdSeXVoX1lVenc5UThDUlFhRzI2Q3B3eWZLWmo1SDVCLXMtbWp5YS1IaFdXZUc3bk9KR0NGTXBmd0JqSHdqQmcwNkZlWnFQc1ZBMC1KZkVXWVhn0gGCAUFVX3lxTE00ZEF4OUJfOWZnRjBKX091Z2ItOFE4ZDdDc1RyUEtXNTNOdDVGTXVPdjQzSzUwRGxQWnNhMnVMeHBDS2VfWWVFeWUxMEh6NTk1RWNFb2IzT1dfSWMyYXlZTEtfaHh5SmIzOGoxZ044V19BWTB6REV5YlZOandCblZ0QlE?oc=5","date":"2025-09-24","type":"pipeline","source":"Fort Worth Star-Telegram","summary":"Fort Worth considers tax breaks to bring medical manufacturing jobs from Europe - Fort Worth Star-Telegram","headline":"Fort Worth considers tax breaks to bring medical manufacturing jobs from Europe - Fort Worth Star","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPVEFGMURqbFQyOFRuQ1FJcDR1ZUNST2xabEw3ZDZBRTQ5elNvdVhzcVlMUTA5VW90SzRveVMyYkdPZlRGam5HLUlYSzhseE9OaS1jS3ZKdWFhS2JfMko1aTB5UG40SFdDZkxMUkkxQkU5Y1hqS2F1OG1kVUQ1NmNDTXJiSEJHT2pTcnYwenN3Umoyby00cUU5Vjl3al9zUkV3dmc?oc=5","date":"2025-05-30","type":"regulatory","source":"Pharmaceutical Business review -","summary":"US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease - Pharmaceutical Business review -","headline":"US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease - Pharmaceutical Business review -","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObTMydGNtQlFXLUpDMGxFSmNoUW8zdVhYcW85aVhWU3lrb2Flem1KNEtHWmVnTDJ4ZzA2dV9xUnlVZVpIOVRVUlhKa3ZqbkVhUFpCY2s5Q2xqNTU0dmJxZEdWMjRrV1FBY084eGMySEdJSjJxb28zWVRYZnliSjZIZk5lU1FEdlBEdkUyUmx0NC1WcjRneElLVlBSVng3d2FOMGZLcVhmM2tTUQ?oc=5","date":"2025-05-29","type":"regulatory","source":"Fierce Pharma","summary":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease - Fierce Pharma","headline":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQWk9KUE9zNV90WGV2ZDFHeUtERFFUNVdaV2FLR3loZEhVbjFFVTFRd3M4UFZjbjZSNkRYRnFNMTRKcENlWHdZSFNOQTYtZzhQYmJ5bDQtallBRGZOOW9hVS00T3ZRUlhpUjhiekhUNFFXOTVkeVRZMXpzb2hFb016azR3Y2l2MzZXMmdKNG9mTlp3U2hxV3lQSGdjZGZzRXNncDBnbHB2WklSWFI1b0Fj?oc=5","date":"2025-03-27","type":"pipeline","source":"Fierce Biotech","summary":"Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO - Fierce Biotech","headline":"Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPS2xtdjMzNGdObU1BcG5Mc0JhdWlrNGxzN2xKMUF2YXNKS2pfNGVXZ1FRUFlJbWJHOGpJOGV1S0tNNXNRSkVzLVZXR3ZPajhMX0EwVHZqZ3E3TnJvWDFkWUtMNDBhR0VoRzh4NTVHWmVtanN2TlFDQ1h0d2ZBVkxmVTM3VGJQa2hmUGpCVUNIczRIanAtRnZr?oc=5","date":"2022-11-22","type":"pipeline","source":"Ophthalmology Times","summary":"Alcon completes acquisition of Aerie Pharmaceuticals - Ophthalmology Times","headline":"Alcon completes acquisition of Aerie Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZ3p0RXNjaDBQckVkZ1FrN3dxMmdKUWI1MVB0U3RHcXJ4Q0NWMnJPa2lwZFJ5UE1EQTE4ZXdwQ3BLYUVWWU5WTXVhR3RidHNqd1paSVJLLXpwY2ZVMmM2RG1ELTFmZ2Vremk4WlIzN0tla1RId2dVUXVXSXdNQVpRdzE0OTNSSmFSLThVQ2lYeWREVHFQNkJ4ZF9MZFRjMWhPYUJqM1hOZkJWUQ?oc=5","date":"2020-01-21","type":"pipeline","source":"Dallas Innovates","summary":"The (Alcon) Family Tree: How One Company Seeded a DFW Life Science Legacy - Dallas Innovates","headline":"The (Alcon) Family Tree: How One Company Seeded a DFW Life Science Legacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQVlQcnBiTmVvWmZQenl5ZW16cW0tV1dwMjhoSEFPQWFJV1lveDZpeUViXy13UElNVENTeWk1VEpzVEpqSlBSM3JzSEtGeG91TjdRUFV1cEMwMEdsOEd6UXl4Z2hLVU1NREN2S3piaGFXdkF1bTBsc2d5WEExVFJnWDU0d0l2anlCX1NvWjlCeHB3MmtYVy1LblNiWTVCR0h0TE1iVmFhbw?oc=5","date":"2019-04-09","type":"regulatory","source":"BioPharma Dive","summary":"Alcon spin-out marks step in Novartis plan to remake business - BioPharma Dive","headline":"Alcon spin-out marks step in Novartis plan to remake business","sentiment":"neutral"}],"patents":[],"drugCount":16,"phaseCounts":{"marketed":15,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}